Trial
NCT01025193
Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pennsylvania
Collaborators
Human Genome Sciences Inc.
Condition
Desensitization
Intervention
Belimumab
Why stopped
has not demonstrated efficacy in primary goal
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-12